The Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying In Q1 2025

We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where The Oncology Institute, Inc. (NASDAQ:TOI) stands against other stocks insiders were buying in Q1 2025.

About 30 minutes before the market closed Monday, the broader market index was up 0.3%, while the blue-chip companies gained 0.9%. Meanwhile, the Nasdaq Composite dropped 0.5%. Some stocks were recovering from Friday losses after inflation data came in higher than expected, coupled with weak consumer sentiment, which heightened concerns about the U.S. economy’s stability, according to Investopedia.

As investors react to daily market changes, ongoing uncertainty continues to affect the market. During such times, insider trading often garners attention, as executive purchases of company stock can signal optimism about the company’s prospects. However, insider sales do not always indicate a lack of confidence—they may be influenced by personal financial reasons or a need for diversification. Executives often follow pre-arranged plans, like 10b5-1, to ensure transparency. While insider trading can offer valuable insights, it should be considered alongside a company’s financial health, market conditions, and industry shifts.

Our Methodology

What are some of the stocks insiders have been buying the most in the first quarter of the year? To find out, we used Insider Monkey’s insider trading stock screener, focusing only on stocks where at least five insiders had purchased shares in January, February, and March. From there, we ranked the 20 stocks with the highest number of insiders purchasing shares.

Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

With each stock, we note the average price per share of these purchases and the stock’s market capitalization.

The Oncology Institute, Inc. (NASDAQ:TOI)

Market Cap: $100.05 million

Number of insiders buying: 8

The Oncology Institute ranks tenth among the 20 stocks that insiders are buying in Q1 2025. It provides medical oncology services in the United States, focusing on adult and senior cancer patients. The company offers a range of services, including physician care, infusion, clinical trials, radiation, and patient support. It also collaborates with Healthy Forge to deliver cancer care services in Southern California.

In a recent development, the company launched the Florida Oncology Network, a fully delegated network aimed at expanding access to high-quality cancer care for Florida residents. The network, which includes TOI Clinics and a panel of oncologists, partners with Provider Network Solutions to enhance care coordination, improve patient outcomes, and expand its reach across the state in 2025.

Dan Virnich, CEO of TOI, stated, “I’m very excited about the launch of Florida Oncology Network and our continued rapid growth in capitated lives in Q1.

For the fourth quarter of 2024, The Oncology Institute reported revenue of $100 million, an increase of 16.9% compared to the prior-year quarter. Gross profit amounted to $15 million, up 1.8% from the same period of 2023. Net loss was $13.2 million, which compares to net loss of $18.8 million in the corresponding quarter of the prior year.

In March, eight insiders, including the company’s CEO, CMO, and COO, acquired a total of around $1.61 million worth of The Oncology Institute shares at an average price of $1.04 per share. Year-to-date the stock is up 277.58% trading at $1.17 per share. However, over the past 12 months, the Oncology Institute shares dropped 24.97%.

Currently, the analyst coverage on The Oncology Institute stock is limited.

Overall, TOI ranks 10th on our list of stocks insiders were buying in Q1 2025. While we acknowledge the potential of TOI our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TOI but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.